Veracyte Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Veracyte Inc 's ROA in the third quarter of 2026?
Veracyte Inc achieved a return on average assets (ROA) of 8.59 % in its third quarter of 2026, this is above VCYT's average return on assets of -18.62%.
Veracyte Inc assets over the 12 months ending in its third quarter of 2026 are valued at $1,476 million

ROA has improved compared to 8.04% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 114 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 988, from total ROA ranking in the second quarter of 2026 at 1399.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	14.96 %	10.58 %	9.14 %	8.02 %	7.24 %
Y / Y Net Income Change	64.62 %	-	307.36 %	704.79 %	26.28 %
Net Income (TTM) in million	127	114	88	66	30
Return On Assets (TTM)	8.59 %	8.04 %	6.34 %	4.88 %	2.27 %
VCYT's Total Ranking	# 988	# 1399	# 1782	# 1836	# 1702
Total Assets (TTM) in million	1,573	1,488	1,436	1,406	1,368
Seq. Total Assets Change	5.72 %	3.6 %	2.16 %	2.74 %	1.69 %
Seq. Net Income Change	23.59 %	-11.21 %	-30.24 %	115.02 %	-

VCYT's 5 Years Annual ROA >> Back to VCYT Management Effectiveness >> Compare VCYT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 4
Sector	# 115
Overall	# 764

Return On Assets Statistics
High	Average	Low
8.04 %	-18.62 %	-52.09 %
(Jun 30 2026)		(Mar 31 2014)

Financial Statements
Veracyte Inc 's Assets	$ 1,573 million	VCYT's Balance sheet
Veracyte Inc 's Income	$ 32 million	Quarterly VCYT's Income Statement
VCYT's Income by Division		See VCYT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	8.02 %	16.65 %	-3.58 %	-2.58 %	159.83 %
Total Assets in million	1,406	1,302	1,116	1,157	1,188
Y / Y Net Income Change	174.89 %	-	-	-	-
Net Income in million	66	24	-74	-37	-76
Annual Return On Assets	4.72 %	1.85 %	-6.67 %	-3.16 %	-6.36 %

VCYT's 5 Years Annual ROA >> Back to VCYT Management Effectiveness >> Compare VCYT ROA to its Competitors

Comment on VCYT's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 4.72 % compared to prior year, due to annual net income growth of 174.89 % to $66.35 million, while value of Veracyte Inc 's overall assets grew just by 8.02 % to $1,406.02 million, compared to $1,406.02 a year before.

More Return On Assets Ratios
VCYT's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VCYT's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VCYT's Competitors
Subscribers only: Roa for Veracyte Inc 's Suppliers
Subscribers only: Return On Assets for VCYT's Customers

You may also want to know
VCYT's Roi	VCYT's Inventory Turnover Ratio	VCYT's Growth Rates	VCYT's Dividend Comparisons
	VCYT's Profitability Ratios	VCYT's Asset Turnover Ratio	VCYT's Dividend Growth
VCYT's Roe	VCYT's Valuation Ratios	VCYT's Financial Strength Ratios	VCYT's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %
Lantheus Holdings Inc	11.43 %
Msa Safety Inc	11.01 %
Encompass Health Corporation	10.99 %
Inspire Medical Systems inc	10.89 %
Transmedics Group Inc	10.67 %
Bristol myers Squibb Company	10.47 %

Date modified: 2026-11-07T13:19:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.